Physician Assistant Program year 2024 Reported 2023–2024 Source: CMS Open Payments, 2026 publication

Steven Sacry

Physician Assistant Whitehall, MT Physician Assistant

NPI 1629064266 CMS profile 10526642

108 First St W, Whitehall, MT 59759

Open in the dashboard

General payments

$189

11 records reported · program years 2023–2024

Research payments

$0

Paid to them · None reported · program years 2023–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Steven Sacry of Whitehall, MT is reported in the CMS Open Payments database as having received $189 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $148 9
2023 General $42 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Sacry
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Steven Sacry were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Steven Sacry Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $42 $167 $52–$557 $160
2024 $148 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2024
  1. Lundbeck LLC $189 11 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2024
  1. Food and Beverage $189 11 payments
Products named General payments · program years 2023–2024
  1. REXULTI $189 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

5,638

Median for Physician Assistant: 241

Drug cost

$225,640

Median for Physician Assistant: $4,110

Branded share of claims

20.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 40 $42,981
Eliquis Apixaban Brand 38 $37,042
Trulicity Dulaglutide Brand 17 $26,187
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 16 $16,219
Ozempic Semaglutide Brand 13 $12,402
Myrbetriq Mirabegron Brand 22 $10,120
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $9,429
Exelon Rivastigmine Brand 12 $8,521
Jardiance Empagliflozin Brand 12 $7,510
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $3,545

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$57,444

Of which drugs: $12,662

Medicare patients

268

Average age 72

Services billed

2,367

135 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 29%
Diabetes 18%
Depression 14%
Ischemic heart disease 9%
Atrial fibrillation 9%
Cancer 8%
Chronic kidney disease 7%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 51 52 $3,873
Sarscv2 vac 30mcg trs-suc im 91320 Office 27 27 $3,747
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 180 $114
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 30 201 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $148
$148 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record